Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 3. Semin Musculoskelet Radiol. 2014 Apr;18(2):149-65. doi: 10.1055/s-0034-1371017. Epub 2014 Apr 8. The role of PET/CT in the evaluation of skeletal metastases. Kannivelu A(1), Loke KS(2), Kok TY(2), Osmany SY(3), Ali SZ(1), Suat-Jin L(4), Ng DC(2). Author information: (1)Department of Diagnostic Radiology, Khoo Teck Puat Hospital, Singapore, Singapore. (2)Department of Nuclear Medicine and PET, Singapore General Hospital, Singapore, Singapore. (3)Radlink PET and Cardiac Imaging Pte Ltd, Singapore, Singapore. (4)Nuclear Medicine and PET Centre, Mount Elizabeth Hospital, Singapore, Singapore. Osseous metastatic disease from malignancy is a common occurrence with significant patient morbidity and mortality as well as increasing health care expenditures. Patient management plans frequently change with the identification of skeletal metastasis and the upstaging of disease status. Bone scintigraphy remains the current mainstay of diagnostic imaging procedures in nuclear medicine for the early detection of skeletal metastasis owing to their high sensitivity. Emerging positron tracers and the increasing use and availability of hybrid single-photon emission computed tomography and positron emission tomography (PET)/computed tomography machines enable physicians to diagnose metastatic disease in bones with superior accuracy. This review introduces the basics of PET and the commonly used positron tracers used to evaluate skeletal metastases. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA. DOI: 10.1055/s-0034-1371017